The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| INKT | +126.37% | N/A | N/A | -90% |
| S&P | +14.78% | +87.14% | +13.33% | +55% |
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$43.65K | 30.3% |
| Market Cap | $63.32M | 113.5% |
| Market Cap / Employee | $2.75M | 0.0% |
| Employees | 23 | -25.8% |
| Net Income | -$2,887.71K | -59.8% |
| EBITDA | -$2,946.02K | -79.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $14.28M | 125.7% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | -100.0% |
| Short Term Debt | $5.73M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -110.63% | 75.1% |
| Return On Invested Capital | 1441.51% | -35.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$941.35K | 68.6% |
| Operating Free Cash Flow | -$941.35K | 68.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -1.41 | -1.75 | -1.34 | -2.22 | 31.25% |
| Price to Tangible Book Value | -15.70 | -1.75 | -1.34 | -2.22 | -87.57% |
| Enterprise Value to EBITDA | -12.92 | -14.56 | -9.13 | -18.21 | 6.98% |
| Total Debt | $4.92M | $5.12M | $5.51M | $5.73M | 24.15% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
